NCT07095452
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07095452
Title A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AbbVie
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Colorado Blood Cancer Institute /ID# 279080 RECRUITING Denver Colorado 80218 United States Details
Willamette Valley Cancer Institute and Research Center /ID# 278721 RECRUITING Eugene Oregon 97401 United States Details
SCRI Oncology Partners /ID# 278353 RECRUITING Nashville Tennessee 37203 United States Details
Texas Oncology - The Woodlands /ID# 278726 RECRUITING The Woodlands Texas 77380 United States Details
Texas Oncology - Northeast Texas /ID# 278725 RECRUITING Tyler Texas 75702 United States Details
Blue Ridge Cancer Care - Roanoke /ID# 278722 RECRUITING Roanoke Virginia 24014 United States Details
Matsuyama Red Cross Hospital /ID# 278660 RECRUITING Matsuyama Ehime 790-8524 Japan Details
University Hospital Kyoto Prefectural University of Medicine /ID# 278156 RECRUITING Kyoto Kyoto 602-8566 Japan Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field